Why is Parmax Pharma falling/rising?

As of 23-Jul, Parmax Pharma Ltd's stock is currently priced at 39.49, reflecting an increase of 0.49 or 1.26%. Today's price summary indicates that the stock has outperformed its sector by 0.75% and has experienced a trend reversal after two consecutive days of decline. However, it is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend. Despite positive results in the last three consecutive quarters and significant growth in net sales, the company faces challenges such as a negative book value and weak long-term fundamental strength, which may contribute to investor caution.
In the broader market context, Parmax Pharma's short-term performance has been underwhelming, with a 1-week return of -2.83% compared to a slight gain of +0.11% in the Sensex. While the stock has shown a positive return of 3.87% over the past month, it has significantly lagged behind the benchmark year-to-date, with a decline of -10.76% versus the Sensex's increase of +5.87%. This disparity highlights the stock's volatility and the potential risks associated with its weak operating profits and high debt servicing challenges, which may deter investors despite recent gains.